PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Psychiatr Serv. Author manuscript; available in PMC 2011 November 23.
Published in final edited form as:
PMCID: PMC3222920
NIHMSID: NIHMS336142

Psychotropic Medication Nonadherence Among United States Latinos: A Comprehensive Review of the Literature

Abstract

Objective

Psychotropic medication nonadherence is a major public health problem, but few studies have focused on Latinos. We systematically reviewed the literature on rates of and factors influencing antipsychotic, antidepressant, or mood stabilizer nonadherence among United States (US) Latinos.

Methods

Data Sources: MEDLINE and PsycINFO were searched using keywords adherence, compliance, Latino, Hispanic, psychotropic, and related terms, as well as bibliographies from relevant reviews and studies.

Study Selection: 21 studies met inclusion criteria: published since 1980 in English or Spanish; measured psychotropic medication nonadherence rates among US Latino adults.

Data Abstraction: We examined articles for study design and objective, location, population, medication type, participant demographics, adherence measure, adherence rates, and factors related to adherence.

Results and Conclusions

In studies including Latinos and other ethnic groups, mean nonadherence rates were 41%, 31%, and 43% among Latinos, Euro-Americans, and African Americans respectively, with an overall effect size of 0.64 between Latinos and Euro-Americans. In studies including only Latinos, the mean nonadherence rate was 44%. Ten of 16 studies found Latinos had significantly lower adherence rates than Euro-Americans. Risk factors for nonadherence included being monolingual Spanish speaking, lacking health insurance, experiencing barriers to quality care, and having lower socioeconomic status. Protective factors included family support and psychotherapy.

Rates of nonadherence to psychotropic medications were higher for Latinos than for Euro-Americans. Further investigation is needed into the potentially modifiable individual and societal level mechanisms of this discrepancy. Clinical and research interventions to improve adherence should be culturally appropriate and incorporate identified factors.

Introduction

Medication nonadherence is a major barrier to favorable health outcomes in psychiatric disorders such as schizophrenia, bipolar disorder, and depression. Suboptimal adherence to psychotropic medications for these disorders has been associated with: relapse; significantly more psychiatric hospitalizations and emergency room visits; poorer mental functioning; lower life satisfaction; more disability related absences from work; greater substance use; increased suicidal behavior; worsened adherence to medications for comorbid medical conditions; and higher health care costs (116).

Unfortunately, nonadherence to antipsychotics, antidepressants, and mood stabilizers is common, with prior reviews of the literature noting rates ranging from 10% to 77% with mean rates of 35–60% (1720). Previous studies have established risk factors for nonadherence including: limited insight; negative attitude or subjective response towards medication; shorter illness duration; comorbid substance abuse; poorer therapeutic alliance; living alone; more self reported side effects; and limited family support (1820). However, many prior reports were significantly limited because they were conducted with predominantly Euro-American populations. Ethnic and racial disparities in adherence have been noted, with prior studies finding that non-white patients were more likely to have lower adherence (3, 2123).

Latinos are the largest and most rapidly growing minority group in the United States, comprising just over 13% of the population (24). More than 40% are foreign born, and 75% are immigrants or children of immigrants (25). Acculturation, “the process by which individuals adopt the attitudes, values, customs, beliefs, and behaviors of another culture” (26), has been found to have mixed health, including mental health, effects for Latinos (2729); Latinos who are less acculturated have lower prevalence rates of psychiatric disorders, but those with a disorder are less likely to receive mental health treatment (30, 31). Given these health and acculturation relationships, acculturation could potentially affect adherence via, for example, physician/patient communication or health literacy. Ethnic differences in prescriptions for and use of (32, 33), dosing needs (34), response to (35), and tolerability of (36, 37) psychotropics have been previously noted for Latinos. However, to our knowledge, there has not yet been a comprehensive review of the literature examining psychotropic adherence among Latinos living in the United States that includes the frequency of, factors associated with, and influences of language and acculturation on nonadherence. Our objectives were to: assess the rate of nonadherence to psychotropic medications among Latinos living in the United States; compare the rate to that of other ethnic minorities and Euro-Americans; and identify any culturally relevant factors influencing adherence among Latinos.

Methods

Data Sources

We searched MEDLINE and PsycINFO databases using combinations of the following keywords: antipsychotic, mood stabilizer, antidepressant, lithium, neuroleptic, psychotropic, schizophrenia, bipolar disorder, depression, adherence, compliance, Latino, Hispanic, ethnicity, Spanish-language, acculturation for articles published since 1980 that measured prevalence of antipsychotic, antidepressant, or mood stabilizer adherence in Latino adults in the United States. Reference lists from recent reviews (1820, 38, 39) were also examined, as were bibliographies from all potentially relevant articles.

Study Selection

We identified 518 papers in those searches. One author then read through every title and identified 214 potentially relevant articles. During that screening, broad inclusion criteria were used, and the only studies excluded were those which clearly examined adherence in non-psychiatric illnesses or medications only (i.e. adherence to Highly Active Anti-Retroviral Therapy in HIV/AIDS), were not in English or Spanish, were only on pediatric populations, or were from outside the United States. A search of the Spanish language literature revealed no potentially relevant studies as all were conducted on populations outside the United States.

The 214 potentially relevant articles were read in detail by one author. To be included studies had to: 1) be on United States populations (including people living in Puerto Rico – although no studies of psychotropic medication adherence included this population); 2) be in English or Spanish (no studies were in Spanish); 3) include Latinos; 4) measure adherence/nonadherence (including self report and medication discontinuation rates) to antidepressants, antipsychotics, and/or mood stabilizers prescribed for depression, schizophrenia, schizoaffective disorder, or bipolar disorder (even if adherence was not the primary focus of the study); and 5a) examine ethnicity as a variable related to adherence and/or report adherence rates of all ethnic groups in the studies (so we could determine whether there were significant differences between ethnic groups), or 5b) for the studies that included only Latino participants, examine adherence and factors influencing adherence.

We excluded studies if they: 1) did not measure separate adherence rates for Latinos; 2) included only children and adolescents; 3) examined medication adherence only for medications that were not antidepressants, antipsychotics, or mood stabilizers; 4) studied adherence to antidepressants, antipsychotics, or mood stabilizers prescribed for diseases other than those listed above (#4 of inclusion criteria; i.e. we excluded studies of anxiety and dementia); 5) reported only study dropout rates, not medication discontinuation or adherence rates, because many factors causing study dropout do not necessarily cause nonadherence. This led to us excluding a widely cited study that found Latinos were more likely to drop out of a clinical trial than were Euro-Americans and identified the reasons for study discontinuation (36).

Data Extraction

Of the 214 initially identified papers, 193 studies were excluded, and 21 were included in our final analysis (1, 6, 4060). The results from one study were reported in two different papers (52, 53), so we counted them as one study. One included study (44) examined adherence-related factors in a subset of another (43), so we counted these as one study and used the nonadherence rate reported for the larger sample (43) in our calculation of the mean nonadherence rate of studies including only Latinos. For each of the 21 studies, two authors examined the study design and objectives, the location and patient population, medications studied, participant characteristics (including preferred language of participants and providers, if reported), measures of adherence, rates of adherence overall and by ethnicity, associations between ethnicity and adherence (including statistical measures), and any other adherence-relevant factors identified. For consistency, we use the terms “adherence” and “nonadherence” throughout the review, replacing the terms “compliance” and “noncompliance”.

Calculation of nonadherence rates

For standardization, if studies reported adherence rates, we calculated nonadherence rates and report those. Because most studies examined only adherence and nonadherence, for studies that reported more adherence categories than adherent and nonadherent (6, 40, 5860), we report all provided rates in Table 1, but for mean nonadherence rate calculations we used the summed partial adherence, nonadherence, and excess filler rates as the nonadherence rate. For the one paper (40) that reported separate adherence rates by ethnicity and diagnosis, we give the separate rates in Table 1, but for calculating mean nonadherence rates, we averaged the rates between diagnoses within each ethnic group. Although no measure of medication adherence is ideal, some have demonstrated more reliability than others. Patient and caregiver reports as well as physician reports of adherence have been shown to underestimate adherence (61, 62), while MEMS caps and calculations from pharmacy fill records (including MPRs, CMPRs, etc.) have been shown to be generally more objective measures (3, 62). Therefore, we also separately analyzed the 11 papers (1, 6, 46, 48, 51, 52, 54, 56, 5860) that used these typically more objective measures.

Table 1
Studies including only US Latinos

Data Analysis and Statistics

For studies that had the data available but had not compared rates of adherence in all ethnic groups separately, we used chi-squares to test significance of differences in adherence rates by ethnicity. We did secondary calculations on study data for 11 studies (3 nonadherence percentage calculations (51, 55, 56), two chi-square tests (50, 57), and six both percentage calculations and chi-square tests (1, 40, 47, 49, 58, 60)). For the two studies (55, 56) in which the unadjusted and adjusted nonadherence rates yielded conflicting results, we included both findings, but used the results of the multivariate analysis when describing comparisons in rates between ethnic groups. We used 2 methods to compare nonadherence rates between ethnic groups: 1) we examined the mean nonadherence rates across studies, including calculating an effect size of the difference between the rate for Latinos and Euro-Americans; and 2) we counted the number of studies that compared rates among ethnic groups, and we report how many of the studies did and did not find significant differences. To calculate the effect size, we used SPSS version 12.0.1 to pool the non-weighted nonadherence means and standard deviations across the studies, and then used an online effect size calculator (http://web.uccs.edu/lbecker/Psy590/escalc3.html). We used online chi-square calculators (www.graphpad.com, http://www.quantpsy.org) for chi-square calculations, and we used SPSS version 12.0.1 for descriptive statistics.

Racial and ethnic group terminology

The terminology for racial and ethnic groups in the literature is highly varied. For the purposes of this review we use the term US Latino to include anyone residing in the US, including Puerto Rico, with Mexican, Central American, South American, Puerto Rican, or Cuban ancestry. We use the terms African American to refer to US residents who trace their ancestry to Africa and Euro-American for US residents with European ancestry. When the included studies used terms such as “Hispanic,” “black,” or “Caucasian”, we replaced those terms with “Latino”, “African American”, and “Euro-American” respectively for standardization. If country of origin of the participants was specified in a study, we include that information. We understand that these definitions have limitations in that they group together people from highly diverse backgrounds. Very few studies reported separate adherence rates for Asian Americans or other ethnic groups, and the number of Asian American or other patients in those studies was typically very small, so we were unable to draw comparisons between nonadherence rates or risk factors between Latinos and those groups.

Results

Description of included studies and prevalence of psychotropic nonadherence

The 21 studies (1, 6, 4060) (Table 1) meeting inclusion criteria showed great heterogeneity in terms of study design and objectives and of population studied. Table 1 shows the four investigations that had only Latino participants, and Table 2 shows the 17 studies that included Latinos and other ethnic groups.

Table 2
Studies including US Latinos and other US ethnic groups

In terms of study design, 13 studies were prospective and eight retrospective. Study objectives varied, with some focusing specifically on adherence (1, 6, 41, 4447, 49, 5160) while others measured adherence as part of studies addressing different questions. Geographically, eight were based in California (6, 42, 43, 47, 48, 50, 54, 55), two in Texas (41, 51), one in New Mexico (52), one in New York (49), one in Connecticut (56), one in Ohio (40), and four were from Veteran’s Administration National Registries (46, 5860), and three were national studies (1, 45, 57).

Twelve reports (N= 12) investigated nonadherence to antipsychotics (1, 6, 4143, 46, 4951, 54, 58, 59), five antidepressants (45, 47, 52, 55, 57), two mood stabilizers (48, 60), and two a combination of these medications (40, 56). Ten studies focused on schizophrenia or schizoaffective disorder (1, 6, 4143, 4951, 59), five on depression (45, 47, 52, 55, 57), three on bipolar disorder (48, 58, 60), and three a combination of those diagnoses (40, 54, 56).

Total N ranged from 40 to 44,637 (mean 6024±13268). Four studies included only Latinos. Of the 17 studies that included both Latinos and other ethnic groups, the percent of Latino participants ranged from 2.9% to 56% (mean 20.3±19.5). Of the seven studies that reported preferred language, the proportion of Spanish-speaking participants ranged from 0–100% (mean 45.7±35.0). Seven studies reported country of origin or ancestry of Latino participants, which was primarily Mexico in four (41, 43, 50, 51), primarily Puerto Rico in two (40, 56), and a mix of Mexico, Guatemala, and El Salvador in one (42).

Studies used a range of adherence measures including: patient report (50, 55); chart review or physician report (41); a combination of patient and family report and chart review (43, 49); medication discontinuation (by patient report) (45, 47, 57); pill counts of returned pills (46); Medication Event Monitoring System (MEMS) pill bottle caps (56); calculations from pharmacy records (including CMGR, MPR, CPR) (1, 6, 48, 51, 52, 5860); urine testing for metabolites (54); and not stated (40, 42). Nineteen studies reported the time period used to examine adherence, which ranged from one week to 48 months (mean 10.2months±10.3).

Nonadherence rates

Three (41, 43, 45) of the four studies including only Latinos (Table 1) reported nonadherence rates, which ranged from 33.0 to 55.0% (mean 44.0±11.0). The fourth explored risk factors for nonadherence in Latinos but did not detail rates and is discussed later (42). Of the 17 studies including Latinos and other ethnic groups (Table 2), 12 (1, 6, 40, 47, 4952, 5658, 60) had data available to compare the nonadherence rates between Latinos and Euro-Americans. The mean rates for Latinos and Euro-Americans were 39.4±15.7 and 29.2±16.5, respectively, yielding an overall effect size of 0.64. Ten of these reports also had data available on African Americans (1, 6, 47, 4951, 5658, 60) and the nonadherence rates in those studies were: Latinos (range 17.2 – 63.1%, mean 41.0±16.3), Euro-Americans (range 10.0–57.2%, mean 31.3±17.2), and African Americans (22.7 – 65.1%, mean 43.2±16.9). Only one study reported separate rates by ethnicity and diagnosis, and showed no difference between nonadherence rates in Latinos with schizophrenia compared to Euro-Americans with schizophrenia, and a nonsignificant trend (p = 0.055) towards Latinos having higher nonadherence rates than Euro-Americans among patients with depression (40).

Comparisons of rates by ethnicity made in individual studies

Sixteen studies evaluated differences in nonadherence rates between Latinos and Euro-Americans. (In addition to the 12 studies that reported nonadherence rates for Latinos and Euro-Americans, 4 other studies measured and compared, but did not detail, nonadherence rates in the two ethnic groups.) Of these 16 studies: six found no statistically significant differences (1, 40, 46, 48, 49, 54); nine reported Latino patients had significantly higher nonadherence rates (6, 47, 5052, 5760); and one found monolingual Spanish-speaking patients, but not bilingual patients, were more likely to be nonadherent than Euro-American patients (56). In ten of 14 studies, African-Americans had significantly greater nonadherence rates than Euro-Americans (1, 6, 46, 49, 51, 54, 56, 5860), while four found no difference (47, 48, 50, 57). A majority of ten studies comparing rates between Latinos and African Americans found no difference (N=7) (1, 47, 4951), while three found Latinos had lower nonadherence rates (54, 58, 60).

Results from studies using more objective measures of adherence

Eleven studies (1, 6, 46, 48, 51, 52, 54, 56, 5860) used MEMs caps, calculations from pharmacy data (including MPR, CPR, CMGR), or urine testing. None of the studies including only Latinos used these methods. Six (1, 6, 51, 56, 58, 60) of the 11 studies had rates by ethnicity available. In those, the mean nonadherence rate among Latinos was 43.7±18.7, for Euro-Americans 36.5±18.9, and for African Americans 49.5±17.7.

Nonadherence related outcomes and factors among Latinos

Five (4145, 56) of the 21 studies included a majority of Latino participants and examined outcomes of and risk and protective factors for nonadherence specifically for Latinos (Table 3).

Table 3
Factors Potentially Related to Adherence Investigated Among United States (US) Latinos

Only one study (56) made cross-cultural comparisons of risk factors, investigating the most significant factors for each ethnic group. Thus, we were unable to answer the question of the relative importance of these identified factors for Latinos compared to other ethnic groups, except through comparisons with prior reviews. Also, there was little overlap between the reports in terms of factors examined. Therefore, direct comparisons of the relative importance of the identified factors were not possible. The one study that made cross cultural comparisons identified older age for monolingual Spanish-speaking Latinos and more years of past treatment and fewer depressive symptoms for Euro-Americans as predictive of higher adherence (56). Nonadherence was found to predict worsened illness course in the two studies examining the health-related outcomes of nonadherence (42, 43).

Language, acculturation, and nonadherence

Only two studies explored the relationship between patient preferred language and nonadherence, and both found monolingual Spanish speakers were significantly more likely to be nonadherent (45, 56), even after controlling for important cofactors, such as age and number of symptoms. In the two studies evaluating the interaction between acculturation and nonadherence, one study found that acculturation was not related to adherence (41), and one found that less acculturated patients were significantly less adherent (42). If one uses language as a proxy for acculturation (6366), then three (42, 45, 56) of four reports (41, 42, 45, 56) found higher nonadherence in less acculturated Latinos. As socioeconomic status is likely a particularly important potential cofactor when examining the relationship between nonadherence and language or acculturation, we examined whether each of these studies controlled for socioeconomic status. Of the studies finding monolingual Spanish speakers were more likely to be nonadherent, one study controlled for socioeconomic status by controlling for education and health insurance status (45), and the other reported that all patients in their study had similar socioeconomic status and access to services (56). In the reports examining acculturation, one controlled for socioeconomic status (41) and found that socioeconomic status, but not acculturation, was significantly associated with nonadherence. The other did not control for socioeconomic status, but the majority of participants were from similarly lower socioeconomic groups (42).

Provider language and ethnicity and nonadherence

One study assessing the effect of provider language found patients who saw a Spanish-speaking non-Latino therapist were less likely to adhere to treatment, but also reported patients treated by a Latino therapist were more likely to adhere (41). The authors found this surprising, and hypothesized that this may have been due to ubiquitous interpretation and translation services available at their clinic. Possibly ethnic concordance with the provider, not language alone, may influence better adherence for Latino patients.

Socioeconomic status, health insurance status and quality of care and nonadherence

Only one study examined the relationship between socioeconomic status and nonadherence and found higher socioeconomic status associated with lower nonadherence (41). Having public or private health insurance (45) was associated with lower nonadherence in the one study that examined this relationship. That study also reported that barriers to accessing quality care led to a higher likelihood of nonadherence (45).

Other nonadherence risk factors

In the studies examining age, two studies found that younger age predicted higher nonadherence in all Latino respondents (41, 45), whereas in a third study, this relationship was found only for monolingual Spanish-speaking participants (56). One study identified problems with a drug of abuse (45) as a risk factor for nonadherence, however, another study found that abstinence from street drugs (marijuana was excluded from the definition) was not significantly related to adherence (44).

Other nonadherence protective factors

Factors associated with better adherence in individual studies included: greater family instrumental support (task-oriented or hands-on assistance) (44); greater financial support from family (41); more “motivation” (as assessed by coming to appointments, requesting refills when due, asking for medication changes if they felt like their medications were not working) (41); being married (45); having more depressive symptoms (45); taking a serotonin selective reuptake inhibitor (SSRI) as opposed to another type of antidepressant (45); and having made 8 or more visits to a nonmedical therapist (45).

Other culturally relevant findings

Sleath et al. (52, 53) reported that in addition to having higher nonadherence rates, Latino patients were significantly less likely than Euro-Americans to both give and receive antidepressant information with their physicians, and were less likely to express complaints about their antidepressants. A study of patients with schizophrenia or depression (40) found Latinos were significantly less likely to characterize their life situation in terms of mental illness compared to Euro-Americans.

Discussion

We reviewed the literature to examine rates of, risk factors for, and influences of language and acculturation on antipsychotic, antidepressant, and mood stabilizer nonadherence among Latinos living in the United States. We found the mean rate of psychotropic nonadherence among Latinos was 44% in studies including only Latinos, and was approximately 40% in studies including multiple ethnic groups. This was higher than the mean rate of roughly 30% among Euro-Americans and was comparable to the rate of roughly 40% among African Americans. The effect size of the difference between rates for Latinos and Euro-Americans was 0.64, suggesting a medium to large difference. We purposely compared rates among ethnic groups using only studies that had rates available for all groups, so the higher nonadherence rates found in Latinos and African Americans compared to Euro-Americans are not due to differences in study design or adherence measure. A majority of individual studies found Latinos had significantly higher rates of nonadherence than Euro-Americans. Remarkably, none found that Latinos had lower nonadherence, even in bilingual, culturally tailored settings (56), suggesting that Latinos experience additional barriers to adherence beyond language and cultural barriers.

Consistent with prior studies, nonadherence predicted worsened illness course in studies that investigated outcomes. Risk factors for nonadherence among Latinos identified in individual studies that are similar to those in the wider adherence literature included substance abuse, barriers to access to quality care, lacking health insurance, and limited family support. Two studies identified monolingual Spanish status as a nonadherence risk factor. If one considers poor English proficiency as a proxy for acculturation (6366), then three of four studies found less acculturation predictive of nonadherence. Protective factors for Latinos included greater family instrumental and financial support, higher socioeconomic status, older age, being married, being more proactive in one’s care, having public or private insurance, and having made 8 or more visits to a therapist.

Prior reviews have noted great variability in psychotropic nonadherence rates (10–77%), with mean rates of 35–60% (1720). The mean rates for Latinos and African Americans were within that mean range, but the Euro-American rate was slightly lower (30%). When examining only studies that used pharmacy data, MEMS caps, or urine testing, the nonadherence rates in all groups were higher (44% for Latinos and 49% for African Americans) and the Euro-American mean nonadherence rate was within the prior literature mean range (37%). Although studies relying on patient or provider report tend to underestimate nonadherence rates, all studies including only Latinos used patient, family, or provider report to measure adherence, yet surprisingly found higher mean nonadherence rates (44%) than studies using more objective measures (40%). This could be due to some using a combination of patient, family and chart review to assess adherence (43, 44). The higher rates could also be due to differences in study design or patient population, or there could be cultural factors that lead to patient and provider report being more reliable in Latino populations than non-Latino populations.

Family likely has a particularly important role in the caring for and health outcomes of Latino patients with mental illness compared to other ethnic groups (24, 38, 67). Two studies investigated which specific types of family assistance were most predictive of adherence and found greater financial support from family (41) and more family instrumental support (“task-oriented” assistance) (44) predictive of better adherence.

Our review has several limitations. Although we conducted a comprehensive search, it is possible we missed a relevant study. This constitutes a comprehensive review of summary data, not a metanalysis. Included studies were heterogeneous with respect to study objectives and design, diagnoses studied, sample size, and proportion of Latino participants. Many of the larger studies were limited by small percentages of Latino patients. Additionally there was extensive variability in adherence measure, time over which adherence was measured (one week to one year), and even the definition of adherence, with some studies using dichotomous measures and others including partially adherent in addition to nonadherent and adherent. This heterogeneity, particularly the variability in time over which adherence was measured, likely led to the wide range in nonadherence rates seen between studies, even among studies using more objective adherence measures, as adherence is known to decrease over time (59). Although this variability could affect the reliability of absolute nonadherence rates, it likely did not affect our ability to compare relative rates between ethnic groups since we included only studies that had rates available for all three groups. Therefore, we know that any ethnic group rate differences were not due to differences in adherence measure or study design. Also, we separately examined studies using only more typically objective adherence measures, and found somewhat higher nonadherence rates among all ethnic groups, but a similar pattern of relative rates between groups to that in the analysis including all reports. Another limitation of the literature was that none of the reports examined every risk or protective factor identified – in fact, many risk and protective factors were investigated only by one or a few studies – making conclusions about the relative importance of each factor impossible to determine. Only one study conducted cross-cultural comparisons of risk or protective factors. Similarly, we could not compare nonadherence rates or factors most relevant by diagnosis and ethnicity because most studies included participants with only one diagnosis. Additionally, a number of factors that likely significantly influence adherence among Latinos were not investigated, such as cultural attitudes and beliefs about mental illness and treatments, health literacy, stigma (68), insight, efficacy and tolerability of medications, side effects, use of alternative treatments, and dietary and genetic effects on medication metabolism. Only a few studies examined factors unique to Latinos such as language and acculturation. Similarly, potentially modifiable mechanisms influencing adherence, such as socioeconomic status, health insurance, or barriers to quality care were merely examined in single reports. We were only able to draw comparisons in rates between Latinos, Euro-Americans, and African Americans due to the literature generally lacking adherence investigations in other ethnic groups. The US Latino population is quite heterogeneous both culturally and in important indicators of population health (24, 28). Many of these studies were conducted with Mexican-Americans and VA populations, so the results are likely not applicable to all Latino communities living in the United States.

It is important to note that the summary mean nonadherence rates were generally unadjusted for potentially important cofactors, such as socioeconomic status. Therefore these cofactors must be considered possible contributors to the lower nonadherence rates seen among Latinos and African Americans compared to Euro-Americans. Similarly, in considering possible explanations for the relationships between risk and protective factors and nonadherence, cofactors such as access to health care or socioeconomic status must be considered. For example, the relationship between less acculturation and nonadherence noted by three of four studies could be mediated by a variety of factors, including socioeconomic status. This remains an open question; two of the four studies examining acculturation did directly control for socioeconomic status, with one still finding an association between nonadherence and less acculturation (45) and the other finding no association (41). Other ways in which less acculturation could lead to nonadherence include impaired patient-physician communication due to language barriers (45) or difficulty navigating the US healthcare system.

Despite these limitations, our results clearly suggest that Latinos are at higher risk for psychotropic medication nonadherence compared to Euro-Americans. Remarkably, this risk was observed across various study designs, diagnostic categories, medication types, clinical settings, and Latino subgroups. The higher rates of nonadherence seen in Latinos were comparable to the rates in African Americans, another disadvantaged ethnic minority. Although the existing literature limited our ability to answer the question of which risk factors are most relevant for Latinos, we have summarized all the influences on adherence in Latinos investigated to date, and identified factors particularly relevant for Latinos.

Research recommendations

As previously recommended (17, 18, 69), a standard definition and measure of adherence would greatly improve the translation of the broader adherence literature. Since people are less than optimally adherent to medications in different ways and for different reasons, quantifying adherence into more subcategories than simply adherent or nonadherent would be helpful in better understanding adherence and developing interventions to improve it. This has been done in more recent studies (6, 5860), one of which, interestingly, found that excess fillers incurred the highest health care costs of all nonadherent patients (6).

In terms of recommendations more specific for studying adherence among Latinos, we first encourage future adherence studies to include more adequate numbers of Latinos. This is consistent with the National Institute of Mental Health’s initiative to increase representation of ethnic minority participants in research studies (70). Given the great heterogeneity of US Latino populations (71), we recommend including Latinos from all the diverse cultural and socioeconomic backgrounds that make up the larger US Latino population, and specifying degree of acculturation, country of origin or cultural background, socioeconomic situation, and preferred language, as was done in many of the included studies. This heterogeneity also gives added weight to prior recommendations for local, community-based, participatory research (38, 72) to develop optimally relevant and lasting interventions to improve adherence. Additionally, we recommend cross-cultural comparisons investigating the relative importance of risk and protective factors for different ethnic groups, including Asians and American Indians – who we noted were rarely included in meaningful numbers in adherence investigations.

While adherence measures that rely on pharmacy records do not require translation, pharmacy records may be liable to underestimate adherence for patients in lower socioeconomic groups, who, for example, may rely on free samples from physicians (which would not be displayed in pharmacy records) to bridge gaps in insurance coverage or reduce prescription costs. Pharmacy records will also exclude herbal and over the counter medications which could affect adherence. Therefore, future studies may want to consider supplementing pharmacy or MEMS caps data with other sources of adherence data, such as patient and family report combined with chart review (44), or detailed structured patient interviews (55) to provide a comprehensive examination of nonadherence and its causes.

Ultimately, research needs to identify mechanisms whereby suboptimal adherence occurs among Latinos and ethnic minorities in general. Hypothesis-driven research characterizing the role of moderators and mediators of adherence is needed. Mechanisms thus identified would be the basis for more effective interventions. Our review gives additional support to the National Institute of Mental Health sponsored expert consensus meeting of Latino Mental Health Services researchers recommendation (38) to investigate the effects on adherence of language, acculturation, family support, health insurance, poverty, and access to quality care including therapy. Given the findings that socioeconomic and health insurance status and barriers to quality care were related to adherence, these should be included as potential cofactors in future analyses of adherence. Particular attention should be paid to including these when comparing ethnic groups, because ethnic differences in adherence have been found to disappear when, for example, income was accounted for (73). As previously noted (56, 65), preferred language may be a better predictor of health patterns than ethnicity. It is essential to include adequate numbers of Spanish-speaking as well as bilingual and English-speaking patients and clinicians in future research to better understand these relationships. In addition to further exploring the influence of factors noted in this review, we hope future studies will investigate other likely adherence influences. One such recently identified factor is stigma, which ranked second only to side effects in antidepressant use concerns identified by Latino focus groups (68). Another is the role of culture in shaping the experience and interpretation of mental illness.

The trend noted in one study (40) that Latinos with depression were more likely to be nonadherent than Euro-Americans with depression (but no difference was found for schizophrenia) deserves focused attention in future investigations. We recommend researchers examine nonadherence rates by both ethnicity and diagnosis. Also, cross-cultural explorations of which factors are most important for which diagnostic groups and whether mechanisms of nonadherence differ between diagnostic and ethnic groups would be a significant new contribution to the literature.

Clinical recommendations

Due to the limitations of the literature described above, we cannot offer specific clinical recommendations at this time. However, the data do provide some general clinical guidelines. Currently there are no evidence-based interventions specifically to improve psychotropic medication adherence among Latinos. However, findings from broader quality improvement interventions (74), adherence interventions in predominantly non-Latino populations (75, 76), adherence interventions for non-psychiatric diseases tested in Latinos (7779), broader mental health interventions for Latinos (80, 81), from clinical experience (82) and policy papers (39) are potentially applicable.

Since the majority of patients are likely to have adherence problems at some point (59), reassessing adherence regularly and repeatedly is important. Incorporating pharmacy records (3) in addition to patient and family report will increase the likelihood of catching adherence difficulties. The finding that Latino patients were less likely than Euro-Americans to discuss their medications with their physician (52, 53) suggests physicians should be particularly mindful to encourage medication discussions with their Latino patients. That physicians are proactive in these discussions is particularly important given that a common practice in many Latino cultures is to show deference towards physicians (83). Depending on language preference and educational attainment, information about medication should be in Spanish and use simple terms enhanced with visual aids, where appropriate. Similarly, the prominence of stigma and culturally-influenced negative antidepressant associations in recent focus groups with Latinos prescribed antidepressants (68), indicates that inquiring about and addressing these could be useful for improving adherence among Latinos.

Given the high prevalence of nonadherence in all populations, and that the reasons for nonadherence are likely different across patients, we strongly recommend assessing adherence and barriers to and mechanisms of adherence individually for every patient. While some factors identified in our review, such as young age, cannot be modified, other contributors to nonadherence could be addressed in clinical settings. The findings by two studies in this review -- that greater family financial and instrumental support were predictive of better adherence --suggest that involving family members in these specific ways whenever possible might be particularly beneficial to Latino patients. In addition, the increased antidepressant adherence among Latinos having 8 or more visits to a non-medical therapist (45) is consistent with findings from predominantly Euro-American samples (57, 84), and a position paper (39) calling for culturally appropriate practice-initiated quality improvement interventions, including psychoeducational and psychotherapeutic components. The finding that Latinos were more likely than Euro-Americans to want counseling and less likely to want antidepressants (85) suggests therapy may be an especially important adherence enhancer for Latinos.

Latinos are least likely of all US ethnic groups to have public or private health insurance, with uninsured rates of 35.7% (compared to 12.6% for Euro-Americans) (86). This disparity lends added significance to the finding that having public or private health insurance predicted better adherence among Latinos (45). As lower socioeconomic status was associated with lower adherence (41), and Latinos are disproportionately represented in lower socioeconomic strata (24, 86) clinicians should pay particular attention to ensuring their patients can afford the psychotropic medications they prescribe. Given barriers to quality care were associated with worse adherence, clinicians can likely improve adherence simply by ensuring they are providing quality care. These findings also suggest that societal level interventions increasing access to health insurance, medications, and quality care would improve adherence.

Culturally and linguistically tailored care is likely important for establishing good clinician-patient relationships, which have been associated with improved adherence (7, 18, 19, 87, 88). Clinicians should attend to cultural contexts shaping how their patients interpret and experience mental illness, as these likely affect adherence. As previously noted in several papers (82, 89, 90), and suggested by the findings of two studies in this review (41, 56), even clinics with primarily bilingual, bicultural staff can have cultural divides with their patients due to socioeconomic and health models and beliefs differences. Recognizing those divides and working collaboratively with patients can help overcome these barriers and improve adherence (82, 91).

Conclusions

US Latinos receiving mental health treatment appear to be at increased risk for psychotropic medication nonadherence compared to Euro-Americans. Our findings suggest that as clinicians and researchers examine ways to improve adherence to psychotropic medications among their Latino patients, important considerations include: prescribing treatment regimens that patients can afford; overcoming barriers to quality care, including language, socioeconomic, and cultural barriers; recognizing family involvement and psychotherapy as potentially important adherence enhancers; and assuring interventions to improve adherence are culturally appropriate.

References

1. Ascher-Svanum H, Faries DE, Zhu B, et al. Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care. Journal of Clinical Psychiatry. 2006;67:453–460. [PubMed]
2. Weiden PJ, Olfson M. Cost of relapse in schizophrenia. Schizophrenia Bulletin. 1995;21:419–429. [PubMed]
3. Valenstein M, Copeland LA, Blow FC, et al. Pharmacy data identify poorly adherent patients with schizophrenia at increased risk for admission. Medical Care. 2002;40:630–639. [PubMed]
4. Terkelsen KG, Menikoff A. Measuring the costs of schizophrenia. Implications for the post-institutional era in the US. Pharmacoeconomics. 1995;8:199–222. [PubMed]
5. Gilbert PL, Harris MJ, McAdams LA, et al. Neuroleptic withdrawal in schizophrenic patients. A review of the literature. Archives of General Psychiatry. 1995;52:173–188. [PubMed]
6. Gilmer TP, Dolder CR, Lacro JP, et al. Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia. American Journal of Psychiatry. 2004;161:692–699. [PubMed]
7. Fenton WS, Blyler CR, Heinssen RK. Determinants of medication compliance in schizophrenia: empirical and clinical findings. Schizophrenia Bulletin. 1997;23:637–651. [PubMed]
8. Goodwin GM. Prophylaxis of bipolar disorder: how and who should we treat in the long term? European Neuropsychopharmacology. 1999;9 (Suppl 4):S125–S129. [PubMed]
9. Mander AJ, Loudon JB. Rapid recurrence of mania following abrupt discontinuation of lithium. Lancet. 1988;2:15–17. [PubMed]
10. Keck PE, Jr, McElroy SL, Strakowski SM, et al. Factors associated with pharmacologic noncompliance in patients with mania. Journal of Clinical Psychiatry. 1996;57:292–297. [PubMed]
11. Tondo L, Jamison KR, Baldessarini RJ. Effect of lithium maintenance on suicidal behavior in major mood disorders. Annals of the New York Academy of Sciences. 1997;836:339–351. [PubMed]
12. Johnson RE, McFarland BH. Lithium use and discontinuation in a health maintenance organization. American Journal of Psychiatry. 1996;153:993–1000. [PubMed]
13. Burton WN, Chen CY, Conti DJ, et al. The association of antidepressant medication adherence with employee disability absences. American Journal of Managed Care. 2007;13:105–112. [PubMed]
14. Geddes JR, Carney SM, Davies C, et al. Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review. Lancet. 2003;361:653–661. [PubMed]
15. Gopinath S, Katon WJ, Russo JE, et al. Clinical factors associated with relapse in primary care patients with chronic or recurrent depression. Journal of Affective Disorders. 2007;101:57–63. [PubMed]
16. Katon W, Cantrell CR, Sokol MC, et al. Impact of antidepressant drug adherence on comorbid medication use and resource utilization. Archives of Internal Medicine. 2005;165:2497–2503. [PubMed]
17. Cramer JA, Rosenheck R. Compliance with medication regimens for mental and physical disorders. Psychiatric Services. 1998;49:196–201. [PubMed]
18. Lacro JP, Dunn LB, Dolder CR, et al. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. Journal of Clinical Psychiatry. 2002;63:892–909. [PubMed]
19. Lingam R, Scott J. Treatment non-adherence in affective disorders. Acta Psychiatrica Scandinavica. 2002;105:164–172. [PubMed]
20. Perlick DA, Rosenheck RA, Kaczynski R, et al. Medication Non-adherence in Bipolar Disorder: A Patient-centered Review of Research Findings. Clinical Approaches in Bipolar Disorders. 2004;3:56–64.
21. Becker MA, Young MS, Ochshorn E, et al. The relationship of antipsychotic medication class and adherence with treatment outcomes and costs for Florida medicaid beneficiaries with schizophrenia. Administration and Policy in Mental Health. 2007;34:307–314. [PubMed]
22. Valenstein M, Blow FC, Copeland LA, et al. Poor antipsychotic adherence among patients with schizophrenia: medication and patient factors. Schizophrenia Bulletin. 2004;30:255–264. [PubMed]
23. Sajatovic M, Elhaj O, Youngstrom EA, et al. Treatment adherence in individuals with rapid cycling bipolar disorder: results from a clinical-trial setting. Journal of Clinical Psychopharmacology. 2007;27:412–414. [PubMed]
24. Ramirez RR, de la Cruz PG. The Hispanic Population in the United States. Available at http://www.census.gov/prod/2003pubs/p20-545.pdf.
25. Rumbaut RG. Ages, life stages, and generational cohorts: decomposing the immigrants first and second generations in the United States. International Migration Review. 2004;38:1160–1205.
26. Abraido-Lanza AF, Armbrister AN, Florez KR, et al. Toward a theory-driven model of acculturation in public health research. American Journal of Public Health. 2006;96:1342–1346. [PubMed]
27. Wells KB, Golding JM, Hough RL, et al. Acculturation and the probability of use of health services by Mexican Americans. Health Services Research. 1989;24:237–257. [PMC free article] [PubMed]
28. Lara M, Gamboa C, Kahramanian MI, et al. Acculturation and Latino health in the United States: a review of the literature and its sociopolitical context. Annual Review of Public Health. 2005;26:367–397. [PubMed]
29. Balls Organista P, Organista KC, Kurasaki K. Relationship Between Acculturation and Ethnic Minority Mental Health. In: Chun KM, Organista PB, Marin G, editors. Acculturation: advances in theory, measurement, and applied research. Vol. 1. Washington, DC: American Psychological Association; 2003. pp. 136–161.
30. Vega WA, Kolody B, Aguilar-Gaxiola S, et al. Gaps in service utilization by Mexican Americans with mental health problems. American Journal of Psychiatry. 1999;156:928–934. [PubMed]
31. Grant BF, Stinson FS, Hasin DS, et al. Immigration and lifetime prevalence of DSM-IV psychiatric disorders among Mexican Americans and non-Hispanic whites in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Archives of General Psychiatry. 2004;61:1226–1233. [PubMed]
32. Virnig B, Huang Z, Lurie N, et al. Does Medicare managed care provide equal treatment for mental illness across races? Archives of General Psychiatry. 2004;61:201–205. [PubMed]
33. Vitiello B, Burnam MA, Bing EG, et al. Use of psychotropic medications among HIV-infected patients in the United States. American Journal of Psychiatry. 2003;160:547–554. [PubMed]
34. Ruiz P, Varner RV, Small DR, et al. Ethnic differences in the neuroleptic treatment of schizophrenia. Psychiatric Quarterly. 1999;70:163–172. [PubMed]
35. Wagner GJ, Maguen S, Rabkin JG. Ethnic differences in response to fluoxetine in a controlled trial with depressed HIV-positive patients. Psychiatric Services. 1998;49:239–240. [PubMed]
36. Sanchez-Lacay JA, Lewis-Fernandez R, Goetz D, et al. Open trial of nefazodone among Hispanics with major depression: efficacy, tolerability, and adherence issues. Depression and Anxiety. 2001;13:118–124. [PubMed]
37. Marcos LR, Cancro R. Pharmacotherapy of Hispanic depressed patients: clinical observations. American Journal of Psychotherapy. 1982;36:505–512. [PubMed]
38. Vega WA, Karno M, Alegria M, et al. Research issues for improving treatment of U.S. Hispanics with persistent mental disorders. Psychiatric Services. 2007;58:385–394. [PubMed]
39. Lewis-Fernandez R, Das AK, Alfonso C, et al. Depression in US Hispanics: diagnostic and management considerations in family practice. Journal of the American Board of Family Practice. 2005;18:282–296. [PubMed]
40. Jenkins JH. Subjective experience of persistent schizophrenia and depression among US Latinos and Euro-Americans. British Journal of Psychiatry. 1997;171:20–25. [PubMed]
41. Hosch HM, Barrientos GA, Fierro C, et al. Predicting Adherence to Medications by Hispanics with Schizophrenia. Hispanic Journal of Behavioral Sciences. 1995;17:320–333.
42. Telles C, Karno M, Mintz J, et al. Immigrant families coping with schizophrenia. Behavioral family intervention v. case management with a low-income Spanish-speaking population. British Journal of Psychiatry. 1995;167:473–479. [PubMed]
43. Karno M, Jenkins JH, de la SA, et al. Expressed emotion and schizophrenic outcome among Mexican-American families. Journal of Nervous and Mental Disease. 1987;175:143–151. [PubMed]
44. Ramirez Garcia JI, Chang CL, Young JS, et al. Family support predicts psychiatric medication usage among Mexican American individuals with schizophrenia. Social Psychiatry and Psychiatric Epidemiology. 2006;41:624–631. [PubMed]
45. Hodgkin D, Volpe-Vartanian J, Alegria M. Discontinuation of Antidepressant Medication Among Latinos in the USA. Journal of Behavioral Health Services and Research. 2007 [PMC free article] [PubMed]
46. Rosenheck R, Chang S, Choe Y, et al. Medication continuation and compliance: a comparison of patients treated with clozapine and haloperidol. Journal of Clinical Psychiatry. 2000;61:382–386. [PubMed]
47. Bull SA, Hu XH, Hunkeler EM, et al. Discontinuation of use and switching of antidepressants: influence of patient-physician communication. JAMA. 2002;288:1403–1409. [PubMed]
48. Li J, McCombs JS, Stimmel GL. Cost of treating bipolar disorder in the California Medicaid (Medi-Cal) program. Journal of Affective Disorders. 2002;71:131–139. [PubMed]
49. Robinson DG, Woerner MG, Alvir JM, et al. Predictors of medication discontinuation by patients with first-episode schizophrenia and schizoaffective disorder. Schizophrenia Research. 2002;57:209–219. [PubMed]
50. Barrio C, Yamada AM, Atuel H, et al. A tri-ethnic examination of symptom expression on the positive and negative syndrome scale in schizophrenia spectrum disorders. Schizophrenia Research. 2003;60:259–269. [PubMed]
51. Opolka JL, Rascati KL, Brown CM, et al. Role of ethnicity in predicting antipsychotic medication adherence. Annals of Pharmacotherapy. 2003;37:625–630. [PubMed]
52. Sleath B, Rubin RH, Huston SA. Hispanic ethnicity, physician-patient communication, and antidepressant adherence. Comprehensive Psychiatry. 2003;44:198–204. [PubMed]
53. Sleath B, Rubin RH, Wurst K. The influence of Hispanic ethnicity on patients’ expression of complaints about and problems with adherence to antidepressant therapy. Clinical Therapeutics. 2003;25:1739–1749. [PubMed]
54. Farabee D, Shen H, Sanchez S. Program-level predictors of antipsychotic medication adherence among parolees. International Journal of Offender Therapy and Comparative Criminology. 2004;48:561–571. [PubMed]
55. Ayalon L, Arean PA, Alvidrez J. Adherence to antidepressant medications in black and Latino elderly patients. American Journal of Geriatric Psychiatry. 2005;13:572–580. [PubMed]
56. Diaz E, Woods SW, Rosenheck RA. Effects of ethnicity on psychotropic medications adherence. Community Mental Health Journal. 2005;41:521–537. [PubMed]
57. Olfson M, Marcus SC, Tedeschi M, et al. Continuity of antidepressant treatment for adults with depression in the United States. American Journal of Psychiatry. 2006;163:101–108. [PubMed]
58. Sajatovic M, Valenstein M, Blow FC, et al. Treatment adherence with antipsychotic medications in bipolar disorder. Bipolar Disorders. 2006;8:232–241. [PubMed]
59. Valenstein M, Ganoczy D, McCarthy JF, et al. Antipsychotic Adherence Over Time Among Patients Receiving Treatment for Schizophrenia: A Retrospective Review. Journal of Clinical Psychiatry. 2006;67:1542–1550. [PubMed]
60. Sajatovic M, Valenstein M, Blow F, et al. Treatment adherence with lithium and anticonvulsant medications among patients with bipolar disorder. Psychiatric Services. 2007;58:855–863. [PubMed]
61. Velligan DI, Wang M, Diamond P, et al. Relationships among subjective and objective measures of adherence to oral antipsychotic medications. Psychiatric Services. 2007;58:1187–1192. [PubMed]
62. Grymonpre RE, Didur CD, Montgomery PR, et al. Pill count, self-report, and pharmacy claims data to measure medication adherence in the elderly. Annals of Pharmacotherapy. 1998;32:749–754. [PubMed]
63. Jeste ND, Moore DJ, Goldman SR, et al. Predictors of everyday functioning among older Mexican Americans vs. Anglo-Americans with schizophrenia. Journal of Clinical Psychiatry. 2005;66:1304–1311. [PubMed]
64. Franzini L, Fernandez-Esquer ME. Socioeconomic, cultural, and personal influences on health outcomes in low income Mexican-origin individuals in Texas. Social Science and Medicine. 2004;59:1629–1646. [PubMed]
65. Folsom DP, Gilmer T, Barrio C, et al. A longitudinal study of the use of mental health services by persons with serious mental illness: do Spanish-speaking Latinos differ from English-speaking Latinos and Caucasians? American Journal of Psychiatry. 2007;164:1173–1180. [PubMed]
66. Vega WA, Sribney WM, Achara-Abrahams I. Co-occurring alcohol, drug, and other psychiatric disorders among Mexican-origin people in the United States. American Journal of Public Health. 2003;93:1057–1064. [PubMed]
67. Guarnaccia PJ, Parra P. Ethnicity, social status, and families’ experiences of caring for a mentally ill family member. Community Mental Health Journal. 1996;32:243–260. [PubMed]
68. Interian A, Martinez IE, Guarnaccia PJ, et al. A qualitative analysis of the perception of stigma among Latinos receiving antidepressants. Psychiatric Services. 2007;58:1591–1594. [PMC free article] [PubMed]
69. Velligan DI, Lam YW, Glahn DC, et al. Defining and assessing adherence to oral antipsychotics: a review of the literature. Schizophrenia Bulletin. 2006;32:724–742. [PMC free article] [PubMed]
70. NIMH Five-Year Strategic Plan for Reducing Health Disparities. 2001 Available at http://www.nimh.nih.gov/about/strategic-planning-reports.
71. Alegria M, Canino G, Shrout PE, et al. Prevalence of mental illness in immigrant and non-immigrant U.S. Latino groups. American Journal of Psychiatry. 2008;165:359–369. [PMC free article] [PubMed]
72. Wells K, Miranda J, Bruce ML, et al. Bridging community intervention and mental health services research. American Journal of Psychiatry. 2004;161:955–963. [PubMed]
73. Gellad WF, Haas JS, Safran DG. Race/ethnicity and nonadherence to prescription medications among seniors: results of a national study. Journal of General Internal Medicine. 2007;22:1572–1578. [PMC free article] [PubMed]
74. Miranda J, Duan N, Sherbourne C, et al. Improving care for minorities: can quality improvement interventions improve care and outcomes for depressed minorities? Results of a randomized, controlled trial. Health Services Research. 2003;38:613–630. [PMC free article] [PubMed]
75. Zygmunt A, Olfson M, Boyer CA, et al. Interventions to improve medication adherence in schizophrenia. American Journal of Psychiatry. 2002;159:1653–1664. [PubMed]
76. Dolder CR, Lacro JP, Leckband S, et al. Interventions to improve antipsychotic medication adherence: review of recent literature. Journal of Clinical Psychopharmacology. 2003;23:389–399. [PubMed]
77. Betancourt JR, Carrillo JE, Green AR. Hypertension in multicultural and minority populations: linking communication to compliance. Current Hypertension Reports. 1999;1:482–488. [PubMed]
78. van Servellen G, Carpio F, Lopez M, et al. Program to enhance health literacy and treatment adherence in low-income HIV-infected Latino men and women. Aids Patient Care and STDS. 2003;17:581–594. [PubMed]
79. Bonner S, Zimmerman BJ, Evans D, et al. An individualized intervention to improve asthma management among urban Latino and African-American families. Journal of Asthma. 2002;39:167–179. [PubMed]
80. Kopelowicz A, Zarate R, Gonzalez SV, et al. Disease management in Latinos with schizophrenia: a family-assisted, skills training approach. Schizophrenia Bulletin. 2003;29:211–227. [PubMed]
81. Patterson TL, Bucardo J, McKibbin CL, et al. Development and pilot testing of a new psychosocial intervention for older Latinos with chronic psychosis. Schizophrenia Bulletin. 2005;31:922–930. [PubMed]
82. Opler LA, Ramirez PM, Dominguez LM, et al. Rethinking medication prescribing practices in an inner-city Hispanic mental health clinic. Journal of Psychiatric Practice. 2004;10:134–140. [PubMed]
83. Erzinger S. Communication between Spanish-speaking patients and their doctors in medical encounters. Culture, Medicine and Psychiatry. 1991;15:91–110. [PubMed]
84. Jamison KR, Gerner RH, Goodwin FK. Patient and physician attitudes toward lithium: relationship to compliance. Archives of General Psychiatry. 1979;36:866–869. [PubMed]
85. Cooper LA, Gonzales JJ, Gallo JJ, et al. The acceptability of treatment for depression among African-American, Hispanic, and white primary care patients. Medical Care. 2003;41:479–489. [PubMed]
86. Kaiser Family F. The Uninsured: A Primer. Available at http://www.kff.org/uninsured/7451.cfm.
87. Cochran SD, Gitlin MJ. Attitudinal correlates of lithium compliance in bipolar affective disorders. Journal of Nervous and Mental Disease. 1988;176:457–464. [PubMed]
88. van Servellen G, Lombardi E. Supportive relationships and medication adherence in HIV-infected, low-income Latinos. Western Journal of Nursing Research. 2005;27:1023–1039. [PubMed]
89. Ruiz P, Ruiz PP. Treatment Compliance Among Hispanics. Journal of Operational Psychiatry. 1983;14:112–114.
90. Lorion RP. Patient and therapist variables in the treatment of low-income patients. Psychological Bulletin. 1974;81:344–354. [PubMed]
91. Sajatovic M, Davies M, Bauer MS, et al. Attitudes regarding the collaborative practice model and treatment adherence among individuals with bipolar disorder. Comprehensive Psychiatry. 2005;46:272–277. [PubMed]
92. Darnell JC, Murray MD, Martz BL, et al. Medication use by ambulatory elderly. An in-home survey. Journal of the American Geriatrics Society. 1986;34:1–4. [PubMed]
93. Cuellar I, Harris LC, Jasso R. An acculturation scale for Mexican-American normal and clinical populations. Hispanic Journal of Behavioral Sciences. 1980;2:199–217.